Table of Content

1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Overview
1.1 Product Overview and Scope of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
1.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Segment by Type
1.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Value Comparison by Type (2024-2034)
1.2.2 TJM-F92 Strain
1.2.3 GDr180 Strain
1.2.4 JXA1-R Strain
1.2.5 Other
1.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Segment by Application
1.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Value by Application: (2024-2034)
1.3.2 Farms
1.3.3 Individual
1.4 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Estimates and Forecasts
1.4.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue 2018-2029
1.4.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales 2018-2029
1.4.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Competition by Manufacturers
2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Manufacturers (2018-2024)
2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Average Price by Manufacturers (2018-2024)
2.4 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Product Type & Application
2.7 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Competitive Situation and Trends
2.7.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Players Market Share by Revenue
2.7.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Retrospective Market Scenario by Region
3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region: 2018-2029
3.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region: 2018-2024
3.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region: 2024-2029
3.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region: 2018-2029
3.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region: 2018-2024
3.3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region: 2024-2029
3.4 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Facts & Figures by Country
3.4.1 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2029)
3.4.3 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Facts & Figures by Country
3.5.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2029)
3.5.3 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Facts & Figures by Country
3.6.1 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2029)
3.6.3 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Facts & Figures by Country
3.7.1 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2029)
3.7.3 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Facts & Figures by Country
3.8.1 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2029)
3.8.3 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2029)
4.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024)
4.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2024-2029)
4.1.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type (2018-2029)
4.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2029)
4.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2024)
4.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2024-2029)
4.2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Type (2018-2029)
4.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Type (2018-2029)
5 Segment by Application
5.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2029)
5.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024)
5.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2024-2029)
5.1.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Application (2018-2029)
5.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2029)
5.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2024)
5.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2024-2029)
5.2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Application (2018-2029)
5.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Yongshun Creatures
6.1.1 Yongshun Creatures Corporation Information
6.1.2 Yongshun Creatures Description and Business Overview
6.1.3 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.1.5 Yongshun Creatures Recent Developments/Updates
6.2 Keqian Biology
6.2.1 Keqian Biology Corporation Information
6.2.2 Keqian Biology Description and Business Overview
6.2.3 Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.2.5 Keqian Biology Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Corporation Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Sinovet
6.4.1 Sinovet Corporation Information
6.4.2 Sinovet Description and Business Overview
6.4.3 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.4.5 Sinovet Recent Developments/Updates
6.5 Elanco
6.5.1 Elanco Corporation Information
6.5.2 Elanco Description and Business Overview
6.5.3 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.5.5 Elanco Recent Developments/Updates
6.6 MSD
6.6.1 MSD Corporation Information
6.6.2 MSD Description and Business Overview
6.6.3 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.6.4 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.6.5 MSD Recent Developments/Updates
6.7 Cahic
6.6.1 Cahic Corporation Information
6.6.2 Cahic Description and Business Overview
6.6.3 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.7.5 Cahic Recent Developments/Updates
6.8 Ringpu
6.8.1 Ringpu Corporation Information
6.8.2 Ringpu Description and Business Overview
6.8.3 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.8.5 Ringpu Recent Developments/Updates
6.9 Baoling
6.9.1 Baoling Corporation Information
6.9.2 Baoling Description and Business Overview
6.9.3 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.9.5 Baoling Recent Developments/Updates
6.10 Jizhong
6.10.1 Jizhong Corporation Information
6.10.2 Jizhong Description and Business Overview
6.10.3 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.10.5 Jizhong Recent Developments/Updates
6.11 Dahuanong
6.11.1 Dahuanong Corporation Information
6.11.2 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Description and Business Overview
6.11.3 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.11.5 Dahuanong Recent Developments/Updates
6.12 Hayao
6.12.1 Hayao Corporation Information
6.12.2 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Description and Business Overview
6.12.3 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.12.5 Hayao Recent Developments/Updates
6.13 Pulike Biology
6.13.1 Pulike Biology Corporation Information
6.13.2 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Description and Business Overview
6.13.3 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.13.5 Pulike Biology Recent Developments/Updates
6.14 Tecon
6.14.1 Tecon Corporation Information
6.14.2 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Description and Business Overview
6.14.3 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolio
6.14.5 Tecon Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Industry Chain Analysis
7.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Production Mode & Process
7.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales and Marketing
7.4.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Channels
7.4.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors
7.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Customers
8 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Dynamics
8.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Industry Trends
8.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Drivers
8.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Challenges
8.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Competitive Situation by Manufacturers in 2022
Table 4. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) of Key Manufacturers (2018-2024)
Table 5. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Average Price (US$/Box) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Product Type & Application
Table 12. Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2018-2024) & (Box)
Table 18. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2018-2024)
Table 19. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2024-2029) & (Box)
Table 20. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2024-2029)
Table 21. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2018-2024)
Table 23. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2024-2029)
Table 25. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (Box)
Table 27. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (Box)
Table 28. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (Box)
Table 32. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (Box)
Table 33. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2018-2024) & (Box)
Table 37. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2024-2029) & (Box)
Table 38. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (Box)
Table 42. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (Box)
Table 43. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (Box)
Table 47. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (Box)
Table 48. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Type (2018-2024)
Table 51. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Type (2024-2029)
Table 52. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type (2018-2024)
Table 53. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type (2024-2029)
Table 54. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Type (2018-2024)
Table 57. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Type (2024-2029)
Table 58. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Type (2018-2024)
Table 59. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Type (2024-2029)
Table 60. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Application (2018-2024)
Table 61. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Application (2024-2029)
Table 62. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Application (2018-2024)
Table 63. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Application (2024-2029)
Table 64. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Application (2018-2024)
Table 67. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Application (2024-2029)
Table 68. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Application (2018-2024)
Table 69. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Application (2024-2029)
Table 70. Yongshun Creatures Corporation Information
Table 71. Yongshun Creatures Description and Business Overview
Table 72. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 73. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 74. Yongshun Creatures Recent Developments/Updates
Table 75. Keqian Biology Corporation Information
Table 76. Keqian Biology Description and Business Overview
Table 77. Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 78. Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 79. Keqian Biology Recent Developments/Updates
Table 80. Boehringer Ingelheim Corporation Information
Table 81. Boehringer Ingelheim Description and Business Overview
Table 82. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 83. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. Sinovet Corporation Information
Table 86. Sinovet Description and Business Overview
Table 87. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 88. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 89. Sinovet Recent Developments/Updates
Table 90. Elanco Corporation Information
Table 91. Elanco Description and Business Overview
Table 92. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 93. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 94. Elanco Recent Developments/Updates
Table 95. MSD Corporation Information
Table 96. MSD Description and Business Overview
Table 97. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 98. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 99. MSD Recent Developments/Updates
Table 100. Cahic Corporation Information
Table 101. Cahic Description and Business Overview
Table 102. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 103. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 104. Cahic Recent Developments/Updates
Table 105. Ringpu Corporation Information
Table 106. Ringpu Description and Business Overview
Table 107. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 108. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 109. Ringpu Recent Developments/Updates
Table 110. Baoling Corporation Information
Table 111. Baoling Description and Business Overview
Table 112. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 113. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 114. Baoling Recent Developments/Updates
Table 115. Jizhong Corporation Information
Table 116. Jizhong Description and Business Overview
Table 117. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 118. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 119. Jizhong Recent Developments/Updates
Table 120. Dahuanong Corporation Information
Table 121. Dahuanong Description and Business Overview
Table 122. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 123. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 124. Dahuanong Recent Developments/Updates
Table 125. Hayao Corporation Information
Table 126. Hayao Description and Business Overview
Table 127. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 128. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 129. Hayao Recent Developments/Updates
Table 130. Pulike Biology Corporation Information
Table 131. Pulike Biology Description and Business Overview
Table 132. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 133. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 134. Pulike Biology Recent Developments/Updates
Table 135. Tecon Corporation Information
Table 136. Tecon Description and Business Overview
Table 137. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 138. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 139. Tecon Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors List
Table 143. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Customers List
Table 144. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Trends
Table 145. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Drivers
Table 146. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Challenges
Table 147. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
Figure 2. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Type in 2022 & 2029
Figure 4. TJM-F92 Strain Product Picture
Figure 5. GDr180 Strain Product Picture
Figure 6. JXA1-R Strain Product Picture
Figure 7. Other Product Picture
Figure 8. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Application in 2022 & 2029
Figure 10. Farms
Figure 11. Individual
Figure 12. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size (2018-2029) & (US$ Million)
Figure 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (2018-2029) & (Box)
Figure 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Average Price (US$/Box) & (2018-2029)
Figure 16. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Report Years Considered
Figure 17. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Manufacturers in 2022
Figure 18. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Players: Market Share by Revenue in 2022
Figure 20. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country (2018-2029)
Figure 23. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country (2018-2029)
Figure 24. United States Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country (2018-2029)
Figure 27. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country (2018-2029)
Figure 28. Germany Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2018-2029)
Figure 35. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country (2018-2029)
Figure 45. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Type (2018-2029)
Figure 55. Global Revenue Market Share of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Type (2018-2029)
Figure 56. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Type (2018-2029)
Figure 57. Global Sales Market Share of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Application (2018-2029)
Figure 58. Global Revenue Market Share of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Application (2018-2029)
Figure 59. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Application (2018-2029)
Figure 60. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Value Chain
Figure 61. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed